Open Access Highly Accessed Research article

Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study

Alessandra Lugaresi111*, Ciro Florio2, Vincenzo Brescia-Morra3, Salvatore Cottone4, Paolo Bellantonio5, Marinella Clerico6, Diego Centonze7, Antonio Uccelli8, Maria di Ioia1, Giovanna De Luca1, Andrea Marcellusi9, Andrea Paolillo10 and for the BRIDGE study group

Author Affiliations

1 Department of Neuroscience and Imaging, University "G. d'Annunzio", Via dei Vestini 31, 66100 Chieti, Italy

2 Multiple Sclerosis Regional Center, Azienda Ospedaliera "Antonio Cardarelli", Via Antonio Cardarelli 9, 80131 Naples, Italy

3 Department of Neurological Science, University of Naples Federico II, Via Giovanni Paladino 39, 80138 Naples, Italy

4 Department of Neurology, Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello, Via Ninni Cassarà, 90146 Palermo, Italy

5 Department of Neurology, Istituto Mediterraneo di Neuroscienze, NEUROMED, Via Atinense 18, 86077 Pozzilli, IS, Italy

6 Division of Neurology, Department of Clinical and Biological Science, University of Turin, Via Giuseppe Verdi 8, 10124 Turin, Italy

7 Department of Neuroscience, University of Rome "Tor Vergata", Via Montpellier 1, 00133 Rome, Italy

8 Department of Neuroscience, Ophthalmology and Genetics, University of Genoa, Via De Toni 5, 16132 Genoa, Italy

9 CEIS Sanità (CHEM-Centre for Health Economics and Management), Faculty of Economics, University of Tor Vergata, Via Columbia 2, 00133 Rome, Italy

10 Merck Serono S.p.A., Via Casilina 125, 00176 Rome, Italy

11 Department of Neuroscience and Imaging, University G. d'Annunzio, c/o Centro Sclerosi Multipla, Ospedale Clinicizzato "SS Annunziata", Via dei Vestini 31, 66100 Chieti, Italy

For all author emails, please log on.

BMC Neurology 2012, 12:7  doi:10.1186/1471-2377-12-7

Published: 5 March 2012

Additional files

Additional file 1:

Figure S1. Type and scheduling of assessments during the 12-week study. Table S1. Baseline characteristics (intent-to-treat population). Figure S2. Most important benefit of the electronic autoinjection system as rated by patients at (a) Week 4, (b) Week 8 and (c) Week 12 (intent-to-treat population). IFN, interferon; im, intramuscular; sc, subcutaneous.

Format: DOC Size: 243KB Download file

This file can be viewed with: Microsoft Word Viewer

Open Data